Susceptibility testing
Antimicrobial agents tested were moxifloxacin, ciprofloxacin (Bayer, Inc., West Haven, CT, USA), ofloxacin (R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA), imipenem (Merck Sharp & Dohme, West Point, PA, USA), piperacillin-tazobactam (WyethAyerst, Pearl River, NY, USA), nalidixic acid, tetracycline, oxacillin, penicillin (Sigma Chemical Co., St Louis, MO, USA), ceftazidime (Glaxo Pharmaceuticals, Research Triangle Park, NC, USA), gentamicin (Schering Corporation, Bloomfield, NJ, USA) and vancomycin (Eli Lilly, Indianapolis, IN, USA), The quinolones were tested against all clinical isolates and mutants. Non-quinolone agents were tested only against parent and mutant strains to determine whether mutational cross resistance emerged to other classes of agents following exposure to quinolones.
Antibiotic susceptibilities were determined by agar dilution methodology using a multipoint inoculator (manufactured by the Physics Machine Shop at Creighton University, Omaha, NE, USA) and an inoculum of 10 4 cfu/spot on Mueller-Hinton agar (CM337, Oxoid Ltd., Basingstoke, UK). 13 The Mueller-Hinton agar was supplemented with 4% NaCl for tests of staphylococci with -lactams, 5% sheep blood for S. pneumoniae, and Haemophilus Test medium supplementation for Haemophilus influenzae. Cultures were incubated for 18-24 h in air, except for S. pneumoniae and H. influenzae which were incubated in 5% CO 2 . Quality control strains were Escherichia coli ATCC 25922, E. coli ATCC 35218, Enterococcus faecalis ATCC 29212, Pseudomonas aeruginosa ATCC 27853, H. influenzae ATCC 49247 and S. pneumoniae ATCC 49619.
The staphylococci were separated into three phenotypic groups on the basis of their susceptibility to ciprofloxacin in agar dilution tests: susceptible (MIC 0.5 mg/L), moderately resistant (1-4 mg/L) and highly resistant ( 8 mg/L). 
Mutational frequencies

Bactericidal activity
Investigations into bactericidal activity were performed with S. aureus strain 41 (oxacillin susceptible), S. aureus strain 27 (oxacillin resistant) and S. pneumoniae strain 212. Stationary-phase cultures were exposed to each fluoroquinolone at multiples of 0.5 , 1 , and 4 MIC and incubated at 37°C in air or 5% CO 2 (S. pneumoniae). Samples were subcultured at intervals of 0, 2, 4, 6 and 24 h for viable counts on Mueller-Hinton or sheep blood (S. pneumoniae only) agar containing 5 mM FeCl 3 to overcome drug carryover.
14 Agar dilution MICs were determined for organisms that showed an increase in numbers after initial killing. Viable counts were compared with drug free control cultures. The lowest countable number obtainable with this procedure was 300 cfu/mL.
Results
Antibiotic susceptibilities
Moxifloxacin was eight-to 32-fold more potent than ciprofloxacin and ofloxacin against staphylococci and S. pneumoniae, and up to eight-fold more potent against enterococci (Table I) . Moxifloxacin was two-to eight-fold more potent against oxacillin-susceptible S. aureus than against oxacillin-resistant S. aureus. Against Enterobacteriaceae, M. catarrhalis and H. influenzae, moxifloxacin was generally up to four-fold less potent than ciprofloxacin, and up to two-fold more potent than ofloxacin. The percentages of isolates susceptible to ciprofloxacin, ofloxacin, nalidixic acid or to 1 mg/L of moxifloxacin are shown in Table I . For all Gram-positive isolates these percentages were 77, 48 and 62% for moxifloxacin, ciprofloxacin and ofloxacin, respectively, while the comparable respective percentages for all Gram-negative isolates were 78, 80 and 76%. Resistance to 2 mg/L of moxifloxacin occurred in S. aureus (nine isolates), coagulase-negative staphylococci (eight isolates), enterococci (four isolates), Serratia marcescens (five isolates), Citrobacter freundii (four isolates), Klebsiella spp. (three isolates), E. coli (two isolates), Enterobacter aerogenes (two isolates) and E. cloacae (one isolate). All S. pneumoniae isolates were inhibited by 0.25 mg/L of moxifloxacin.
Susceptibilities to moxifloxacin of S. aureus strains with varying resistance to ciprofloxacin are shown in Table II. Moxifloxacin was approximately eight-fold more potent than ciprofloxacin against ciprofloxacin-susceptible strains (MIC of ciprofloxacin 0.5 mg/L), and was approximately 32-fold more potent against moderately ciprofloxacin resistant (MIC 1-4 mg/L) and highly ciprofloxacinresistant (MIC 8 mg/L) strains. A comparable increase in relative potency was also seen in tests with coagulasenegative staphylococci (data not shown). Moxifloxacin was two-to four-fold more potent than ciprofloxacin against ciprofloxacin-susceptible coagulase-negative strains, approximately eight-fold more potent against moderately ciprofloxacin-resistant strains and approximately 32-fold more potent against highly ciprofloxacin-resistant strains. Moxifloxacin was consistently eight-to 16-fold more potent than ofloxacin against staphylococci, with no significant change in the relative potencies of the two agents as quinolone resistance increased.
Mutant studies
The ability of the quinolones to select less susceptible single-step mutants was determined by exposing eight isolates to superinhibitory concentrations of each agent. Mutants were selected from all eight strains exposed to ciprofloxacin, and from six and five strains exposed to moxifloxacin and ofloxacin, respectively. A total of 32 mutants were selected. Of these, 69% and 63% were susceptible to 1 mg/L of moxifloxacin and ciprofloxacin, respectively, and 31% were susceptible to 2 mg/L of ofloxacin. When only mutants selected at the highest concentration of each quinolone were considered, mutational frequencies ranging from 10 6 to 10 8 were obtained for 17 of the 20 (85%) single-step mutants recovered.
Concurrent decreases in susceptibility to non-quinolone agents were detected in mutants selected from two Gramnegative organisms. Two of five mutants selected from K. pneumoniae strain 130 exhibited 16-fold increases in MIC of imipenem (from 0.12 to 2 mg/L). These mutants were selected with moxifloxacin and ciprofloxacin. Two out of eight mutants selected with ofloxacin from M. catarrhalis BT84 exhibited four-fold increases in the MIC of tetracycline (from 1 to 4 mg/L).
Effect of de-novo quinolone resistance on subsequent development of quinolone resistance
Attempts were made to select successive single-step mutants from a single strain each of S. aureus and S. epidermidis. Using moxifloxacin and ciprofloxacin as selecting agents it was not possible to select less susceptible mutants of S. aureus strain 255 with moxifloxacin. First-, secondand third-step mutants however, were selected with ciprofloxacin, each at a frequency of 10 7 . After three mutational steps, the MICs of ciprofloxacin and ofloxacin were 128 mg/L, whereas the MIC of moxifloxacin was only 4 mg/L (Table III) .
In tests with S. epidermidis strain 1, first-and second-step mutants were selected after exposure to moxifloxacin at a mutational frequency of 10 9 , but no subsequent-step mutants were selected with this agent (Table III) . Greater mutational frequencies (10 5 - 10 7 ) were detected when first-, second-and third-step mutants were selected with ciprofloxacin. The third-step mutant selected with ciprofloxacin exhibited MICs of 1, 64 and 16 mg/L for moxifloxacin, ciprofloxacin and ofloxacin, respectively.
A first-step mutant of S. pneumoniae strain 212 was selected only with exposure to ciprofloxacin. No subsequent-step mutants were selected with either ofloxacin, moxifloxacin or ciprofloxacin.
Bactericidal activity against S. aureus and S. pneumoniae
Initial inocula were 4.4 10 5 cfu/mL, 5.5 10 4 cfu/mL and 5.6 10 5 cfu/mL for S. aureus strain 41 (oxacillinsusceptible), S. aureus strain 27 (oxacillin-resistant) and S. pneumoniae strain 212, respectively. All quinolones tested were bactericidal ( 3 log 10 decrease in viable count) against each strain at concentrations four-fold above the MIC, as shown in Figures 1, 2 and 3 . Ofloxacin was also bactericidal at its MIC against S. aureus strain 41. Less susceptible mutants of S. aureus strain 41 were selected at the MIC and half the MIC of ciprofloxacin, and at half the MIC of moxifloxacin. Less susceptible mutants of S. aureus strain 27 were selected at the MIC of each agent. The concentrations of each drug to inhibit all staphylococcal mutants were 0.25 mg/L of moxifloxacin and 2 mg/L of ciprofloxacin and ofloxacin. No mutational decreases in susceptibility were detected in tests with S. pneumoniae strain 212.
Discussion
High potency and low potential for mutational selection are desired features of an antimicrobial agent. The current study confirmed the greater potency of moxifloxacin compared with ciprofloxacin and ofloxacin against Grampositive organisms including oxacillin-resistant S. aureus. Moreover, in contrast to many studies of predominantly highly-susceptible isolates, [6] [7] [8] [9] moxifloxacin and ofloxacin were found to have comparable activity to ciprofloxacin against this collection of Gram-negative isolates which included many isolates with reduced susceptibility to ciprofloxacin. This finding should be interpreted against the perspective that the study did not include P. aeruginosa (an organism against which ciprofloxacin is highly active), 1, 5, 6, 12, 14 and also the presumption of a susceptible moxifloxacin breakpoint of 1 mg/L.
The reason for moxifloxacin being less affected than ciprofloxacin by mechanisms responsible for increasing quinolone resistance in staphylococci were not investigated. However, this finding was consistent with other reports in which ciprofloxacin was noted to be more affected than some other quinolones by quinolone resistance mechanisms in staphylococci and in other types of bacteria. 5, [14] [15] [16] This feature of moxifloxacin, coupled with its enhanced potency against a variety of Gram-positive pathogens, suggests that it should be a suitable candidate for clinical evaluation. 
